Upadacitinib

Introduction Overview

Generic Name

upadacitinib

Brand Name

Rinvoq

Dosage Form

oral extended-release tablets (15 mg, 30 mg, and 45 mg), oral solution (1 mg/mL)

Drug Class

Antirheumatics; Janus kinase (JAK) inhibitors

Pharmacokinetics

Absorption:
Upadacitinib is administered orally and is available as extended-release tablets and an oral solution. It exhibits rapid absorption, with peak plasma concentrations typically occurring within 2 to 4 hours post-dose when taken in the extended-release tablet form. The presence or absence of food does not significantly impact its bioavailability, making it convenient for outpatient use. Clinical studies have shown moderate oral bioavailability, and extended-release formulations ensure steady plasma concentrations over a 24-hour period. The absorption may be minimally influenced by gastrointestinal pH or motility but remains generally consistent across populations.

Distribution:
After absorption, upadacitinib distributes widely in the body. It demonstrates moderate plasma protein binding, primarily to albumin, at approximately 52%. The volume of distribution is around 45 L, indicating moderate tissue distribution, including penetration into inflamed tissues, which is relevant for its therapeutic effect in inflammatory diseases. Distribution into the central nervous system is limited. There is no extensive accumulation in fat tissue, and steady-state concentrations are achieved within several days of consistent dosing.

Metabolism:
Upadacitinib is metabolized predominantly by the cytochrome P450 enzyme CYP3A4, with a minor contribution from CYP2D6. The main metabolic pathways include oxidative metabolism leading to hydroxylated metabolites. These metabolites have low pharmacological activity compared to the parent compound. Co-administration of strong CYP3A4 inhibitors (e.g., ketoconazole) can increase plasma exposure, warranting dose modifications or avoidance. Conversely, CYP3A4 inducers (e.g., rifampin) decrease upadacitinib plasma levels, potentially reducing efficacy.

Elimination:
The elimination half-life of upadacitinib ranges between 9 to 14 hours, supporting once-daily dosing in most indications. Upadacitinib and its metabolites are eliminated mainly via urine (~38%) and feces (~24%), with approximately 79% of the dose recovered through these routes. Renal excretion involves both parent drug and metabolites, and hepatic clearance via metabolism is significant. Special populations with impaired renal or hepatic functions may require dose adjustments to prevent accumulation and adverse effects.

Dosage Forms

Available Dosage Forms:
Rinvoq is available in two main formulations which are not interchangeable:
- Oral extended-release tablets in 15 mg, 30 mg, and 45 mg strengths
- Oral liquid solution (Rinvoq LQ) at 1 mg/mL concentration

Dosages for Adults and Adolescents:
- Rheumatoid Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis (Adults): 15 mg orally once daily
- Psoriatic Arthritis (Adults): 15 mg orally once daily
- Psoriatic Arthritis (Children 2 to <18 years, ≥10 kg): Dosage based on body weight (oral solution)
- Atopic Dermatitis (Adults <65 and children ≥12, ≥40 kg): Initiation at 15 mg once daily, escalating to max 30 mg once daily if no response
- Atopic Dermatitis (Adults ≥65 years): 15 mg once daily
- Ulcerative Colitis (Adults): Induction 45 mg once daily for 8 weeks; maintenance 15 mg once daily (30 mg may be considered for refractory cases)
- Crohn's Disease (Adults): Induction 45 mg once daily for 12 weeks; maintenance 15 mg once daily (30 mg may be considered for refractory cases)
- Giant Cell Arteritis (Adults): 15 mg orally once daily with corticosteroid tapering, monotherapy following corticosteroid discontinuation
- Polyarticular Juvenile Idiopathic Arthritis (Children ≥2 years): Weight-based dosing using oral solution

Specific Patient Populations:
- Renal impairment: Dose modification may be needed, especially in severe impairment
- Hepatic impairment: Caution advised, dose adjustments may be necessary
- Not recommended in patients with severe lymphopenia, neutropenia, or anemia
- Not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants
- Pediatric patients (≥2 years) have dosing based on weight with liquid formulation

Clinical Guidelines:
The lowest effective dose to maintain therapeutic response is recommended to minimize risk of adverse events. Patients should be carefully monitored for side effects and laboratory parameters. Dose escalation is reserved for inadequate response, particularly in atopic dermatitis and inflammatory bowel disease indications.

Mechanism Of Action

Upadacitinib, the active ingredient in Rinvoq, is a selective Janus kinase 1 (JAK1) inhibitor. The JAK family of tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) mediates intracellular signaling of numerous cytokines and growth factors important for hematopoiesis, immune function, and inflammation. By selectively inhibiting JAK1, upadacitinib disrupts the phosphorylation and activation of signal transducers and activators of transcription (STATs), key transcription factors involved in gene expression that drive inflammatory and immune responses.

The selectivity for JAK1 over other JAK isoforms allows upadacitinib to effectively attenuate pro-inflammatory cytokines such as interleukins (IL-6, IL-12, IL-23) and interferons, while minimizing effects on JAK2-mediated hematopoietic signaling. This targeted inhibition reduces inflammatory cell activation, proliferation, and the release of inflammatory mediators, leading to clinical improvement in autoimmune and inflammatory conditions.

Upadacitinib’s intracellular mechanism affects multiple signaling pathways simultaneously, distinguishing it from monoclonal antibodies that target single cytokines or cell surface receptors. This broad immunomodulatory effect explains its efficacy across different diseases such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, inflammatory bowel diseases, and others.

Clinical studies have demonstrated that inhibition of JAK1 reduces disease activity, joint inflammation, synovial damage, and skin lesions. Compared to other JAK inhibitors (e.g., tofacitinib, baricitinib), upadacitinib’s high selectivity may provide an improved safety profile, especially regarding hematologic adverse effects. However, long-term safety data continue to evolve. Overall, upadacitinib modulates immune dysregulation at the molecular level to provide a comprehensive anti-inflammatory effect across multiple chronic inflammatory and autoimmune disorders.

Pharmacological Actions

Selective inhibition of Janus kinase 1 (JAK1), disrupting cytokine signaling pathways involved in inflammation and immune response.
Reduction of pro-inflammatory cytokine activity including interleukin-6 (IL-6), IL-12, IL-23, and interferon gamma.
Suppression of immune cell activation, proliferation, and migration contributing to decreased tissue inflammation.
Immunomodulatory effects that decrease pathological autoimmune responses in various inflammatory diseases.
Inhibition of STAT phosphorylation leading to decreased gene transcription of inflammatory mediators.
Reduction of synovial inflammation and joint destruction in rheumatoid arthritis and psoriatic arthritis.
Alleviation of skin inflammation and pruritus in atopic dermatitis through modulation of immune pathways.
Attenuation of intestinal inflammation in ulcerative colitis and Crohn’s disease by targeting immune cell signaling.
Dose-dependent pharmacodynamic effects allowing titration to balance efficacy and safety.
Oral administration with systemic activity, providing an alternative to injectable biologic therapies.
Potential steroid-sparing effects when used in combination with corticosteroids in giant cell arteritis.
No significant inhibition of JAK2 or JAK3 at therapeutic doses, minimizing hematopoietic toxicity.
Ability to be used as monotherapy or in combination with other conventional DMARDs.
Rapid onset of action with clinical improvements often seen within weeks of initiation.
Broad clinical application related to targeting intracellular signaling in multiple autoimmune diseases.

Therapeutic Or Clinical Uses

Treatment of moderate to severe rheumatoid arthritis in adults with inadequate response or intolerance to tumor necrosis factor (TNF) inhibitors.
Management of active psoriatic arthritis in adults who have failed or are intolerant to TNF inhibitor therapy.
Treatment of moderate to severe atopic dermatitis (eczema) in adults and children 12 years and older who are refractory to other systemic therapies.
Induction and maintenance therapy for moderate to severe ulcerative colitis in adults refractory to TNF inhibitors or conventional treatments.
Induction and maintenance treatment for moderate to severe Crohn’s disease in adults not responding to TNF antagonist medications.
Management of ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults with inadequate response to TNF inhibitors.
Treatment of giant cell arteritis in adults, in combination with corticosteroids or as monotherapy after corticosteroid tapering.
Treatment of active polyarticular juvenile idiopathic arthritis in children aged 2 years and older with inadequate TNF blocker response.
Alternative therapy for patients unable to tolerate or respond to biologic DMARDs and other immunosuppressive agents.
Potential use to reduce reliance on systemic corticosteroids in chronic inflammatory conditions.
Off-label usage under clinical discretion for other autoimmune disorders characterized by JAK-STAT pathway dysregulation.
Part of combination therapy regimens with methotrexate or other conventional DMARDs.
Use in inflammatory arthritis conditions where aggressive immunomodulation is necessary to prevent joint damage.
Treatment of inflammation-associated dermatologic manifestations resistant to topical or systemic therapies.
Improvement of quality of life by reducing disease activity, pain, swelling, and physical disability in autoimmune diseases.

Side Or Adverse Effects

Increased risk of serious infections including bacterial, viral, fungal, and opportunistic infections due to immunosuppression.
Upper respiratory tract infections and nasopharyngitis are common adverse events.
Nasopharyngitis, bronchitis, influenza-like illness reported frequently during treatment.
Herpes zoster reactivation including shingles with painful skin rash.
Gastrointestinal perforation risk, especially in patients on concomitant NSAIDs, corticosteroids, or with diverticulitis history.
Elevations in liver enzymes and abnormal hepatic function tests.
Laboratory abnormalities including neutropenia, lymphopenia, anemia, and changes in platelet counts.
Increased risk of malignancies including lymphoma, lung cancer, and skin cancers; long-term safety is still under surveillance.
Thromboembolic events such as deep vein thrombosis, pulmonary embolism, and arterial thromboses including myocardial infarction and stroke.
Gastrointestinal symptoms including nausea and abdominal pain.
Common side effects like headache, acne or rash, folliculitis, and cold symptoms such as sneezing and sore throat.
Weight gain observed in patients treated for atopic dermatitis but not commonly reported in other indications.
Injection or administration site reactions with the oral solution preparation rarely reported.
Fatigue or tiredness, sometimes associated with anemia or infection.
Rare reports of hypersensitivity reactions including anaphylaxis, angioedema, and urticaria.

Precautions

Screen for active or latent infections, including tuberculosis, prior to starting therapy.
Avoid use in patients with severe immunodeficiency or active serious infections.
Use with caution in patients with history of recurrent infections or chronic lung disease.
Monitor blood counts regularly as neutropenia, lymphopenia, and anemia can occur.
Assess hepatic and renal function before and periodically during treatment.
Avoid concomitant use with other potent immunosuppressants or biologic DMARDs.
Vaccinate patients appropriately before initiation; avoid live vaccines during therapy.
Advise patients to avoid exposure to known infections and report symptoms promptly.
Caution in patients with history of gastrointestinal ulcers or diverticulitis due to perforation risk.
Consider cardiovascular risk factors as therapy may increase major adverse cardiovascular events.
Use in pregnancy only if benefits outweigh risks; effective contraception required during treatment and for weeks after cessation.
Breastfeeding is contraindicated during treatment and for at least 6 days after last dose.
Consider risks in patients with a history of malignancy; monitor for signs or symptoms of cancer.
Evaluate and monitor lipid profiles and manage dyslipidemia appropriately.
Advise patients to avoid grapefruit products due to potential interaction increasing drug levels.

Warnings

Boxed warning for increased risk of serious infections, including tuberculosis, fungal, viral, and bacterial infections that can be fatal.
Risk of malignancies such as lymphoma, lung cancer, and skin cancer with long-term use.
Potential for major adverse cardiovascular events (MACE) including heart attack and stroke.
Risk of thrombosis including deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis.
Risk of gastrointestinal perforations, especially in patients on NSAIDs, corticosteroids, or with diverticular disease.
Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported.
Patients with prior or current hepatitis B infection at risk of reactivation; monitor carefully.
Use not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants.
Use with caution in elderly patients who may have increased risk of adverse events.
Patients should be closely observed for signs of infection, malignancy, or cardiovascular events during therapy.
Interruption or discontinuation of therapy may be needed based on severity of adverse reactions.
Live vaccines should not be given concurrently due to immunosuppression.
Pregnancy warning: Teratogenic risk; use effective contraception.
Breastfeeding is contraindicated due to potential exposure of the infant to the drug.
Prompt medical attention required for signs of infection, cardiac events, or thrombotic symptoms.

Contraindication

Known hypersensitivity to upadacitinib, Rinvoq, or any excipients in the oral tablets or solution.
Concurrent use with other Janus kinase inhibitors or biologic DMARDs.
Use in patients with active serious infections including tuberculosis, bacterial, viral, or fungal infections.
Severe immunodeficiency or active malignancies where immunosuppression is contraindicated.
Patients with severe hepatic impairment without ability to monitor and adjust therapy.
Absolute lymphocyte count (ALC) less than 500 cells/mm3, absolute neutrophil count (ANC) less than 1000 cells/mm3, or hemoglobin less than 8 g/dL.
Pregnancy unless risk-benefit assessment supports use; contraindicated due to teratogenicity.
Breastfeeding during treatment and for an advised period after the last dose.
Known hypersensitivity to any component of the formulation including inactive ingredients.
Use in combination with potent immunosuppressants such as azathioprine and cyclosporine.
Patients receiving live virus vaccines concurrently.
Patients with history of gastrointestinal perforations who cannot be closely monitored.
Known severe hypersensitivity or anaphylactic reaction during previous JAK inhibitor therapy.
Concomitant use with strong CYP3A4 inducers without appropriate dose adjustment.
Patients with uncontrolled cardiovascular disease at high risk for thrombotic events without close monitoring.

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) increase plasma levels of upadacitinib, increasing risk of toxicity.
CYP3A4 inducers (e.g., rifampin, phenytoin) decrease upadacitinib levels, potentially reducing efficacy.
Co-administration with strong immunosuppressants such as azathioprine or cyclosporine may increase infection risk and is not recommended.
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, naproxen may increase risk of gastrointestinal perforation when used concomitantly.
Corticosteroids (e.g., prednisone, dexamethasone) combined with Rinvoq may potentiate immunosuppression and infection risk.
Potential additive hematologic toxicities with other drugs causing cytopenias.
Avoid live vaccines during and following Rinvoq treatment to prevent vaccine-derived infections.
Concomitant use with other JAK inhibitors or biologic DMARDs increases risk of serious infections and is contraindicated.
Grapefruit and grapefruit juice may increase upadacitinib plasma concentration.
Drugs that affect immune function (e.g., methotrexate, sulfasalazine) should be used cautiously in combination.
Possible pharmacodynamic interaction with anticoagulants and antiplatelet drugs requiring close monitoring.
Interactions with antifungal agents like voriconazole and posaconazole can modify drug levels.
Drugs affecting liver enzymes (inducers/inhibitors) necessitate dose adjustments due to alteration in metabolism.
Monitoring for enhanced adverse reactions is crucial when combined with other immunomodulatory therapies.
Drug interaction profile requires thorough medication reconciliation including over-the-counter and herbal supplements.

Preparations Of The Drug

Rinvoq extended-release oral tablets available in 15 mg, 30 mg, and 45 mg strengths.
Rinvoq LQ oral solution formulated at 1 mg/mL concentration intended for pediatric and specialized dosing.
Tablets contain inactive excipients such as colloidal silicon dioxide, hypromellose, mannitol, and titanium dioxide.
Oral solution includes excipients like citric acid anhydrous, sodium benzoate, sodium citrate dihydrate, and sucralose.
Both tablet and liquid formulations should be stored at controlled room temperatures, protected from moisture and heat.
Rinvoq LQ solution should be discarded 60 days after opening.
Tablets are to be swallowed whole and not crushed, chewed, or broken to maintain extended-release properties.
Liquid formulation dosing requires use of the provided syringe and adapter for accurate measurement and administration.
Packaging includes child-resistant containers with clear labeling for dose and expiration.
No known generic versions currently approved; manufacturing is by AbbVie Inc.
Both formulations have distinct pharmacokinetic profiles and are not interchangeable.
Manufactured under stringent quality controls to ensure potency and purity.
Patient instructions include handling and storage guidelines to preserve drug stability.
No preservative used in oral tablets; oral solution contains sodium benzoate as a preservative.
Rinvoq formulations are FDA-approved for multiple inflammatory conditions with precise dosing guidelines.